Guidelines currently recommend the early use of second-generation androgen receptor signaling inhibitors (ARSIs) in both castrate-resistant and -sensitive metastatic prostate cancer (with or without chemotherapy) and also in biochemical non-metastatic castrate-sensitive relapse. The gene discussed is AR; the disease is metastatic prostate carcinoma.